Ukraine's defense minister confirms collaborative efforts with SpaceX have yielded initial success in countering Russia's unauthorized use of Starlink terminals to guide attack drones, with a new verification system imminent.
Former Iranian President Hassan Rouhani has issued a stark warning to the regime, urging sweeping reforms to address public grievances as internal divisions surface following a deadly crackdown on protests. The rare public criticism from within the establishment highlights growing tensions ahead of renewed nuclear talks.
The United States is conducting multi-day air force exercises in the Middle East, showcasing rapid deployment capabilities, as former President Donald Trump renews threats of military action against Iran unless it returns to nuclear negotiations. The drills occur against a backdrop of heightened rhetoric and regional unease.
A federal judge's sharply worded order releasing a detained migrant father and son has ignited a political firestorm, with prominent Republicans demanding impeachment and decrying judicial overreach.
IDEAYA Biosciences shares have retreated from recent highs, sparking debate among investors. While a discounted cash flow model suggests deep undervaluation, price-to-sales metrics paint a contrasting picture of a premium stock. We examine the numbers behind the volatility and what it signals for the precision oncology company's future.
Fresh financial data from QuidelOrtho reveals ongoing challenges, including constant currency revenue declines and pressured cash flow, forcing investors to weigh the stock's risk-reward profile as its momentum appears to fade.
While Wall Street chases the latest weight-loss drug headlines, Novo Nordisk's recent launch of an oral GLP-1 therapy and its entrenched insulin business present a compelling value proposition for long-term investors.
French pharmaceutical giant Sanofi has discontinued development of its experimental mRNA flu vaccine, citing a strategic reprioritization. The decision comes as influenza activity remains high across much of the United States, with significant hospitalizations and deaths reported this season.
A multi-year investigation in North Georgia has led to the indictment of nine individuals accused of running a sophisticated scheme that falsified vehicle paperwork, enabling unlicensed drivers to illegally purchase and register cars while netting over $1 million.
While analysts project another year of strong gains for the S&P 500, two key long-term valuation metrics are flashing red, reaching levels historically associated with major market downturns.
Speculation mounts over a potential merger between Tesla and SpaceX, part of a broader strategic realignment under Elon Musk that could see Tesla shift focus from electric vehicles to humanoid robots and autonomous taxis, with xAI potentially in the mix.
For recipients hit with a sudden overpayment notice, a formal request to reduce the withholding rate can provide crucial financial breathing room.
Despite its leadership in high-demand defense sectors like drones and hypersonics, Kratos Defense & Security's shares face sustained pressure as investors question its sky-high valuation and cash flow.
A wave of experienced investors on Reddit are sharing the pivotal financial and psychological benchmarks that convinced them to leave their W2 jobs behind. The consensus? It's less about net worth and more about sustainable cash flow, strategic planning, and navigating hidden hurdles like financing and healthcare.
As the IRS sharpens its focus on digital assets, experts warn that new reporting forms and stringent tracking requirements make accurate crypto tax filing more critical than ever. Missteps could lead to severe penalties.
Amid a backdrop of cautious market optimism, companies with significant insider ownership are drawing investor attention. We examine three firms where those closest to the business are putting their money, spanning biotech, advanced semiconductors, and regional banking.
IDEXX Laboratories (IDXX) reported robust double-digit growth for Q4 2025, driven by record placements of its premium diagnostic instruments and expanding test utilization. While acknowledging persistent softness in U.S. veterinary visit volumes, the company outlined a confident initial 2026 forecast, banking on its innovation pipeline and the transformative impact of its inVue Dx system.
Exxon Mobil's fourth-quarter results surpassed expectations, driven by record production in the Permian Basin and Guyana alongside significant cost savings. While the strong performance has propelled the stock higher, analysts are divided on whether its current valuation fully prices in future growth or exposes investors to downside risk.
The Supreme Court of British Columbia has granted final approval for Coeur Mining's acquisition of New Gold, moving the deal into its final regulatory phase. The transaction, poised to significantly expand Coeur's precious metals footprint, advances as the miner's stock shows considerable strength over the past year.
Shares of Japanese financial giant ORIX (TSE:8591) have shown mixed short-term performance, yet a deeper look reveals robust 90-day and one-year returns. With the stock trading at ¥4,627, analysts debate whether the market is overlooking intrinsic value or correctly pricing future growth amid a global shift towards alternative capital.
